T. Rowe Price Associates’s Sonnet BioTherapeutics SONN Stock Holding History

T. Rowe Price Associates’s Portfolio SONN Stock Details SONN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-18	Closed	-$19K	–	3015
2021 Q4	$19K	Hold	18	–	–	﹤0.01%	2963
2021 Q3	$27K	Hold	18	–	–	﹤0.01%	2925
2021 Q2	$71K	Hold	18	–	–	﹤0.01%	2877
2021 Q1	$101K	Buy	+18	New	+$114K	﹤0.01%	2780

Other funds holding SONN

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

CAM

Campion Asset Management Falls Church, Virginia $164M AUM 25.8% 1-Year Est. Return

T. Rowe Price Associates's SONN Position: Q1 2022 in Review

T. Rowe Price Associates sold out of Sonnet BioTherapeutics (SONN) in Q1 2022, closing a stake of 18 shares — an estimated $19K sold.

T. Rowe Price Associates first reported a position in SONN in Q1 2021 and held it in 4 quarters. The position peaked at $101K in Q1 2021. 22 funds tracked by Wall St. Rank hold SONN as of Q1 2022.

T. Rowe Price Associates reported no remaining Sonnet BioTherapeutics position as of Q1 2022 after selling out during the quarter.
T. Rowe Price Associates sold 18 Sonnet BioTherapeutics shares in Q1 2022, an estimated $19K.
T. Rowe Price Associates first reported a position in Sonnet BioTherapeutics in Q1 2021 and held it in 4 quarters.
T. Rowe Price Associates's Sonnet BioTherapeutics position peaked at $101K in Q1 2021.
22 funds tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q1 2022.

Based on T. Rowe Price Associates's 13F filing for Q1 2022, filed 16 May 2022.